The life science industry in Denmark has developed into one of the strongest clusters in Europe. With excellent interplay between public and private partners and a unique test environment, Denmark turns clinical research into business. For many years, Denmark has constituted an international health laboratory, attracting international businesses and researchers.

Reasons include the presence of several different types of healthcare industries, a long-standing tradition for efficient public-private partnerships, plus a keen political focus on creating framework conditions conducive to research and business development in healthcare and welfare.

Over the past five decades, the Indian life sciences sector has witnessed exponential growth both in terms of broadening of scope and deepening of capabilities across the industry value chain. One of the key challenges the sector faces is the need for a strong collaboration between life science and healthcare companies not just on products but also on solutions to help meet the demand-supply mismatch. The need of the hour is for the product-push models to be complemented with service-oriented models that place a high priority on patients’ interests.

  • Life_science_Denmark_India The Danish biotechnology cluster is a major world player, especially in areas such as enzymes, CNS research, diabetes care and cancer research. A long-standing agricultural tradition created a research industry in Denmark more than 150 years ago and since then, research methods have continuously developed in Denmark. The biotech industry emerged in the 1970s as a new recombinant DNA technology was published. With the help of recombinant DNA, also referred to as genetic engineering proteins can be produced, such as human insulin and other drugs in cells that are grown under controlled conditions. Since then, biotechnology created more than 200 new medicines and vaccines, including drugs to treat diabetes, cancer, HIV/AIDS and autoimmune diseases. Biotechnology is also the cause of hundreds of diagnostic tests. Top 3 reasons for collaborating with Danish export companies or placing biotech business activities in Denmark:

    • Denmark has the largest commercial drug development pipeline in Europe (Ernst and Young, 2015)
    • Denmark is ranked the best country in Europe for development of biotechnology (Scientific American, 2016)
    • Denmark is one of the most R&D intensity countries in the world, and the best in Europe regarding researcher concentration (Bloomberg Innovation Index, 2016)


  • The MedTech/medico industry in Denmark is well-reputed abroad for a number of leading companies within diagnostics, disposables and assistive technology. These companies are prominent in Danish business and industry and spearhead a strongly positioned Danish MedTech industry, which, measured in exports per capita, is one of the largest in the world. The medical devices industry is sustained by innovation and product R&D, and Danish enterprises benefit from an array of well-established innovation centers distributed throughout Denmark.

    The Medical Devices industry in India is presently valued at USD 5.2 billion and contributes 4-5% to the USD 96.7 billion Indian health care industry. Currently, India has about 750–800 medical device manufacturers in the country, with an average investment of Rs 170–200 million and an average turnover of Rs 450–500 million.

    The industry has steadily grown and witnessed a surge from USD 2.02 billion in 2009 to USD 3.9 billion in 2015 at a Compound Annual Growth Rate (CAGR) of 15.8%. As per industry estimates, the Indian medical devices market will grow to USD 50 billion by 2025. Currently, India is counted among the top 20 global medical devices market and is the 4th largest medical devices market in Asia after Japan, China and South Korea. Equipment and Instruments (surgical and non-surgical) form the largest segment (53% of the Indian medical device industry), constituting about USD 2.7 Billion (2017), while the estimated market size of the consumer and durable segment is USD 1404 million.

  • The Danish healthcare system is universal and based on the principles of free and equal access to healthcare for all citizens. The healthcare system offers high-quality services, the majority of which is financed by general taxes.

    Most importantly, we place the patient at the center of attention and design our healthcare sector to support this idea. We combine sophisticated technology and transmission of data with a strong focus on skills and coherent processes. We prioritize design and quality and innovate by involving users and public-private cooperation. Combined, these trademarks lead to cost-efficient care and solutions that are practically applicable. In short, our success is the result of a well-functioning public sector supported by innovative companies that provide the technologies, products, and expertise which make it possible. We are not perfect, but we have come far and push forward to tackle modern healthcare challenges intelligently.

    Danish healthcare innovation is not exclusive for the Danes: many years of global presence show that our healthcare products and solutions create value internationally. Danish ideas and products are used every day in ambulances, medical clinics, hospitals, and nursing homes across the world.

    The healthcare sector in India is currently at a cusp. Issues of access, affordability, quality of care and efficiency remain significant. A number of reports have been published about the poor health status of India, compared to its Low and Middle-Income Country (LMIC) peers. India is also facing an unprecedented pressure due to the poor reach of quality healthcare to millions of its citizens due to issues of access and affordability. The Indian healthcare sector has faced shortages of workforce and infrastructure.

    Inequity in access, affordability and quality of healthcare are the major concerns that the country is grappling with on one hand; and on the other hand, it needs a strategic approach to leverage the growth trajectory of healthcare to its advantage. Given this complexity of the sector and the unique situation of the country in healthcare, it is evident that a single stakeholder cannot offer all the solutions and address all the challenges. Collaboration, thus, becomes a pre-requisite for success.

    As per industry reports, healthcare is poised to grow at an estimated annual rate of 19 per cent to reach USD 280 billion by 2020 with India being recognized as a destination for world class healthcare. During the last decade the private sector grew to become the major provider of healthcare services. The Indian government has also introduced several reforms. The 11th and 12th Five Year Plans and international focus on the Millennium Development Goals have led to successes, especially in the primary health area – maternal and child health, and infectious diseases.

Links & References

Reports
Video